Key result
Transcatheter edge-to-edge repair guided solely by echocardiography was feasible and safe, achieving a sustained reduction of mitral regurgitation to ≤2+ in 90.4% of patients at 1-year follow-up.
Why the study?
TEER treats mitral regurgitation, but the high radiation exposure during the procedure is associated with adverse effects for medical staff.
Does transcatheter edge-to-edge repair guided solely by echocardiography safely and effectively reduce mitral regurgitation in patients with symptomatic MR?
Cohort (n=23)
No
Does transcatheter edge-to-edge repair guided solely by echocardiography safely and effectively reduce mitral regurgitation in patients with symptomatic MR?
p-value: p=<0.001
Transcatheter edge-to-edge repair guided solely by echocardiography without fluoroscopy is feasible, safe, and effective for reducing mitral regurgitation in selected patients.
Background: Transcatheter edge-to-edge repair (TEER) of the mitral valve has emerged as an alternative treatment for mitral regurgitation (MR). However, the high radiation exposure during the process has been associated with multiple adverse effects for medical staff. In this study, we assessed the feasibility and safety of TEER performed solely under the echocardiographic (echo) guidance. Methods: Between April 2021 to August 2021, we retrospectively collected characteristics of 23 patients with MR who underwent TEER under echocardiographic guidance exclusively. Follow-up evaluations were performed at 1- , 3-months and 1-year post procedure. Results: All 23 patients (mean age, 66.1 ± 12.1 years; 65.2% males) successfully underwent echo-guided TEER, with 22 patients under transesophageal echo (TEE) guidance and 1 patient under transthoracic echo (TTE) guidance for severe esophageal stenosis. Of the patients, 60.9% received 1 implant and 39.1% received 2 implants. The median total procedural time was 130 (interquartile range, IQR: 90–150) min and the device procedure time was 73 (IQR: 58–100) min. The median length of stay was 6 (IQR: 5–9) days. At 3-months follow-up, 63.6% of patients had an MR ≤1+ and 90.9% had an MR ≤2+ (p < 0.001 vs. baseline). Improvement in functional status was observed, with 40.9% of patients classified as New York Heart Association (NYHA) functional class I and 45.5% as NYHA functional class II (p < 0.001 compared to baseline) at 3-months. At 1-year follow-up, 90.4% maintained MR reduction with MR ≤2+ (p < 0.001 vs. baseline). Single leaflet device attachment (SLDA) occurred in one patient (4.3%) 1-week post procedure. Conclusions: This retrospective, single-center, and pilot study demonstrates the feasibility, safety, and low complication rates of TEER guided solely by echocardiography. Our findings support the systematic use of echocardiography as the sole guidance modality for TEER, highlighting its potential as an alternative to fluoroscopy-guided procedures. Further multicenter and comparative studies are warranted to confirm these results and provide a more comprehensive evaluation of this approach.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2023) conducted a cohort in Mitral regurgitation (n=23). Echocardiography-guided transcatheter edge-to-edge repair (TEER) was evaluated on Mitral regurgitation ≤2+ at 1-year follow-up (p=<0.001). Transcatheter edge-to-edge repair guided solely by echocardiography was feasible and safe, achieving a sustained reduction of mitral regurgitation to ≤2+ in 90.4% of patients at 1-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: